| Revision as of 13:25, 21 October 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (changes to verified fields - added verified revid - updated 'ChemSpiderID_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'CAS_number_Ref') per Chem/Drugbox validation (report ...← Previous edit |
Latest revision as of 21:54, 30 November 2023 edit undoCitation bot (talk | contribs)Bots5,433,514 edits Add: doi-access. | Use this bot. Report bugs. | Suggested by Neko-chan | #UCB_webform 110/200 |
| (11 intermediate revisions by 9 users not shown) |
| Line 1: |
Line 1: |
|
⚫ |
{{Short description|Monoclonal antibody}} |
|
{{Drugbox |
|
{{Drugbox |
|
| Verifiedfields = changed |
|
| Verifiedfields = changed |
|
| verifiedrevid = 456674000 |
|
| verifiedrevid = 477243250 |
|
|
<!-- Monoclonal antibody data --> |
|
|
|
| ⚫ |
<!--Monoclonal antibody data--> |
|
|
| type = mab |
|
| type = mab |
|
| mab_type = F(ab')2 |
|
| mab_type = F(ab')2 |
|
| source = o |
|
| source = o |
|
| target = ] |
|
| target = ] |
|
⚫ |
<!-- Clinical data --> |
|
|
|
|
|
| tradename = |
| ⚫ |
<!--Clinical data--> |
|
|
| tradename = |
|
| pregnancy_AU = |
|
| pregnancy_AU = |
|
| pregnancy_US = |
|
| pregnancy_US = |
|
| pregnancy_category = |
|
| pregnancy_category = |
|
| legal_AU = |
|
| legal_AU = |
|
| legal_CA = |
|
| legal_CA = |
|
| legal_UK = |
|
| legal_UK = |
|
| legal_US = |
|
| legal_US = |
|
| legal_status = |
|
⚫ |
| routes_of_administration = |
|
| legal_status = |
|
|
⚫ |
<!-- Pharmacokinetic data --> |
| ⚫ |
| routes_of_administration = |
|
|
|
| bioavailability = |
|
|
|
|
⚫ |
| protein_bound = |
| ⚫ |
<!--Pharmacokinetic data--> |
|
|
| bioavailability = |
|
| metabolism = |
|
⚫ |
| elimination_half-life = |
| ⚫ |
| protein_bound = |
|
|
| metabolism = |
|
| excretion = |
|
⚫ |
<!-- Identifiers --> |
| ⚫ |
| elimination_half-life = |
|
|
| excretion = |
|
|
|
|
| ⚫ |
<!--Identifiers--> |
|
|
| CAS_number_Ref = {{cascite|changed|??}} |
|
| CAS_number_Ref = {{cascite|changed|??}} |
|
| CAS_number = 156227-98-4 |
|
| CAS_number = 156227-98-4 |
|
|
| UNII_Ref = {{fdacite|correct|FDA}} |
|
|
| UNII = 6SC756X51V |
|
| ATC_prefix = L04 |
|
| ATC_prefix = L04 |
|
| ATC_suffix = AB03 |
|
| ATC_suffix = AB03 |
|
| PubChem = |
|
| PubChem = |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank = |
|
| DrugBank = |
|
| KEGG_Ref = {{keggcite|correct|kegg}} |
|
| KEGG_Ref = {{keggcite|correct|kegg}} |
|
| KEGG = D07436 |
|
| KEGG = D07436 |
|
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
|
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|
| ChemSpiderID = NA |
|
| ChemSpiderID = none |
|
⚫ |
<!-- Chemical data --> |
|
|
|
|
|
| chemical_formula = |
| ⚫ |
<!--Chemical data--> |
|
|
| chemical_formula = |
|
| molecular_weight = |
|
|
|
|
| molecular_weight = |
|
|
}} |
|
}} |
|
'''Afelimomab''' ('''MAK 195F''') is an anti-] ]. Administration of afelimomab reduces the concentration of ]-6 in patients with ], but reduces ] only marginally.<ref>{{pmid|16277704}}</ref><ref>{{pmid|15640628}}</ref> |
|
'''Afelimomab''' ('''MAK 195F''') is an anti-] ]. Administration of afelimomab reduces the concentration of ]-6 in patients with ], but reduces ] only marginally.<ref>{{cite journal | vauthors = Rondon E, Venkataraman R | title = Afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels | journal = Critical Care | volume = 9 | issue = 5 | pages = E20 | date = August 2005 | pmid = 16277704 | pmc = 1297624 | doi = 10.1186/cc3798 | doi-access = free }}</ref><ref>{{cite journal | vauthors = Panacek EA, Marshall JC, Albertson TE, Johnson DH, Johnson S, MacArthur RD, Miller M, Barchuk WT, Fischkoff S, Kaul M, Teoh L, Van Meter L, Daum L, Lemeshow S, Hicklin G, Doig C | display-authors = 6 | title = Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels | journal = Critical Care Medicine | volume = 32 | issue = 11 | pages = 2173–82 | date = November 2004 | pmid = 15640628 | doi = 10.1097/01.CCM.0000145229.59014.6C | author17 = Monoclonal Anti-TNF: a Randomized Controlled Sepsis Study Investigators | s2cid = 23321488 }}</ref> |
|
|
|
|
|
==References== |
|
== References == |
|
{{reflist}} |
|
{{reflist}} |
|
|
|
|
| Line 55: |
Line 52: |
|
|
|
|
|
] |
|
] |
|
|
|
|
|
|
|
|
{{monoclonal-antibody-stub}} |
|
{{monoclonal-antibody-stub}} |
|
{{antineoplastic-drug-stub}} |
|
{{antineoplastic-drug-stub}} |
|
|
|
|
] |
|
